Cargando…
Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884251/ https://www.ncbi.nlm.nih.gov/pubmed/33600920 http://dx.doi.org/10.1016/j.annonc.2021.02.008 |
| _version_ | 1783651372995969024 |
|---|---|
| author | Trojaniello, C. Vitale, M.G. Ascierto, P.A. |
| author_facet | Trojaniello, C. Vitale, M.G. Ascierto, P.A. |
| author_sort | Trojaniello, C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7884251 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | European Society for Medical Oncology. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78842512021-02-16 Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 Trojaniello, C. Vitale, M.G. Ascierto, P.A. Ann Oncol Letter to the Editor European Society for Medical Oncology. Published by Elsevier Ltd. 2021-05 2021-02-16 /pmc/articles/PMC7884251/ /pubmed/33600920 http://dx.doi.org/10.1016/j.annonc.2021.02.008 Text en © 2021 European Society for Medical Oncology. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Trojaniello, C. Vitale, M.G. Ascierto, P.A. Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
| title | Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
| title_full | Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
| title_fullStr | Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
| title_full_unstemmed | Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
| title_short | Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19 |
| title_sort | checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884251/ https://www.ncbi.nlm.nih.gov/pubmed/33600920 http://dx.doi.org/10.1016/j.annonc.2021.02.008 |
| work_keys_str_mv | AT trojanielloc checkpointinhibitortherapyforskincancermaybesafeinpatientswithasymptomaticcovid19 AT vitalemg checkpointinhibitortherapyforskincancermaybesafeinpatientswithasymptomaticcovid19 AT asciertopa checkpointinhibitortherapyforskincancermaybesafeinpatientswithasymptomaticcovid19 |